Cantor Fitzgerald
Cantor Fitzgerald is a leading brokerage service for Wall Street's fixed income inter-dealer community. Cantor is a recognized leader in the specialized areas of equity and fixed income capital markets, offering an impressive array of products and services to more than 5000 institutional clients around the world.
Cantor suffered a devastating loss on September 11, 2001, when the World Trade Center terrorist attacks claimed the lives of 658 of the company's 960 New York-based employees.
Howard W. Lutnick is the company's Chairman and CEO.
-
Nicox to present at the 2017 BIO International Convention
-
Nicox: Issuing and admission to trading on the Euronext regulated market in Paris of 597,897 new shares awarded to existing Aciex shareholders following the US FDA's approval of ZERVIATE
-
Nicox receives FDA approval of ZERVIATE1 (cetirizine ophthalmic solution) 0.24%
-
Ms. Lauren P. Silvernail appointed to Nicox Board of Directors
-
Nicox announces the presentation of scientific data on NCX 667 at ARVO 2017
-
Nicox first quarter 2017 business update and cash position
-
Nicox to present at Cantor Fitzgerald's 2nd Annual Healthcare Conference
-
Nicox to transfer Commercial Operations to new pan-European Ophthalmic Specialty Pharmaceutical Company led by GHO Capital
-
Nicox added to Russell Global Index
-
U.S. FDA grants Priority Review for Nicox's AC-170 New Drug Application
-
Nicox first quarter 2016 financial and business update
-
Nicox announces the presentation of scientific data at ARVO 2016
-
Nicox submits New Drug Application for AC-170 to U.S. FDA

